Research
Hormonal
A fatty liver actively overproduces cardiovascular risk factors, including VLDL, glucose, CRP, and coagulation factors, thereby increasing the risk of type 2 diabetes and cardiovascular disease.
Treating fatty liver is not just about liver health; it is a primary strategy for preventing heart disease and diabetes. Reducing liver fat through lifestyle changes or medication lowers the production of harmful substances like VLDL and inflammatory markers.
GoodSupportsHIGH confidence
This is easily explained by the fact that the liver, once fatty, overproduces most of the known cardiovascular risk factors such as very low density lipoprotein (VLDL), glucose, C-reactive protein (CRP), plasminogen activator inhibitor-1 (PAI-1), fibrinogen and coagulation factors.
Why this rating
Supported by multiple human studies and animal models cited in the review.
Source
Fat in the liver and insulin resistance
Hannele Yki‐Järvinen · Annals of Medicine · 2005
DOI 10.1080/07853890510037383
narrative_reviewCited 266×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Intrahepatic triglyceride content is the most proximate correlate of insulin resistance, independent of subcutaneous fat mass or overall obesity.Good
- PPAR-gamma agonists (thiazolidinediones) reduce liver fat and increase adiponectin levels, whereas metformin does not significantly reduce liver fat content.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →